Emerging drugs for prostate cancer

Paul H. Chung, Bishoy A. Gayed, Gregory R. Thoreson, Ganesh V. Raj

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Introduction: Androgen deprivation therapy is the mainstay treatment for patients with prostate cancer who are not candidates for definitive treatment, are diagnosed with advanced disease on initial presentation or progress after primary treatment. Patients who stop responding to androgen deprivation therapy develop castration resistant prostate cancer (CRPC). Emerging drugs undergoing clinical evaluation and drugs that have recently received FDA approval for the treatment of CRPC are reviewed. Areas covered: As the natural history and signaling pathways of prostate cancer are better understood, new treatments and targeted therapies will be developed. The FDA recently approved 5 medications that increase survival in patients with CRPC. Additional medications and drug classes are being explored that may eventually lead to new treatment options. Articles were identified using a PubMed database search. Expert opinion: Recent FDA medication approvals and the development of emerging treatments are promising for the future of patients with prostate cancer. The addition of new medications challenges physicians to identify the optimal sequence and/or combination in which newer and older medications should be administered. Physicians treating patients with prostate cancer have a growing responsibility to keep pace with these new medications so that they may counsel and treat patients appropriately.

Original languageEnglish (US)
Pages (from-to)533-550
Number of pages18
JournalExpert Opinion on Emerging Drugs
Volume18
Issue number4
DOIs
StatePublished - Dec 2013

Fingerprint

Prostatic Neoplasms
Pharmaceutical Preparations
Castration
Therapeutics
Androgens
Physicians
Drug Evaluation
Expert Testimony
Natural History
PubMed
Databases
Survival

Keywords

  • Abiraterone
  • Androgen deprivation therapy
  • Androgen receptor
  • Antiandrogens
  • Cabazitaxel
  • Castration resistance
  • Denosumab
  • Docetaxel
  • Emerging drugs
  • Enzalutamide
  • Prostate cancer
  • PSA-TRICOM
  • Radium-223
  • Sipuleucel-T
  • Zoledronic acid

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging drugs for prostate cancer. / Chung, Paul H.; Gayed, Bishoy A.; Thoreson, Gregory R.; Raj, Ganesh V.

In: Expert Opinion on Emerging Drugs, Vol. 18, No. 4, 12.2013, p. 533-550.

Research output: Contribution to journalArticle

Chung, Paul H. ; Gayed, Bishoy A. ; Thoreson, Gregory R. ; Raj, Ganesh V. / Emerging drugs for prostate cancer. In: Expert Opinion on Emerging Drugs. 2013 ; Vol. 18, No. 4. pp. 533-550.
@article{39d3bcba435d495d96408041e3a06a5f,
title = "Emerging drugs for prostate cancer",
abstract = "Introduction: Androgen deprivation therapy is the mainstay treatment for patients with prostate cancer who are not candidates for definitive treatment, are diagnosed with advanced disease on initial presentation or progress after primary treatment. Patients who stop responding to androgen deprivation therapy develop castration resistant prostate cancer (CRPC). Emerging drugs undergoing clinical evaluation and drugs that have recently received FDA approval for the treatment of CRPC are reviewed. Areas covered: As the natural history and signaling pathways of prostate cancer are better understood, new treatments and targeted therapies will be developed. The FDA recently approved 5 medications that increase survival in patients with CRPC. Additional medications and drug classes are being explored that may eventually lead to new treatment options. Articles were identified using a PubMed database search. Expert opinion: Recent FDA medication approvals and the development of emerging treatments are promising for the future of patients with prostate cancer. The addition of new medications challenges physicians to identify the optimal sequence and/or combination in which newer and older medications should be administered. Physicians treating patients with prostate cancer have a growing responsibility to keep pace with these new medications so that they may counsel and treat patients appropriately.",
keywords = "Abiraterone, Androgen deprivation therapy, Androgen receptor, Antiandrogens, Cabazitaxel, Castration resistance, Denosumab, Docetaxel, Emerging drugs, Enzalutamide, Prostate cancer, PSA-TRICOM, Radium-223, Sipuleucel-T, Zoledronic acid",
author = "Chung, {Paul H.} and Gayed, {Bishoy A.} and Thoreson, {Gregory R.} and Raj, {Ganesh V.}",
year = "2013",
month = "12",
doi = "10.1517/14728214.2013.864635",
language = "English (US)",
volume = "18",
pages = "533--550",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Emerging drugs for prostate cancer

AU - Chung, Paul H.

AU - Gayed, Bishoy A.

AU - Thoreson, Gregory R.

AU - Raj, Ganesh V.

PY - 2013/12

Y1 - 2013/12

N2 - Introduction: Androgen deprivation therapy is the mainstay treatment for patients with prostate cancer who are not candidates for definitive treatment, are diagnosed with advanced disease on initial presentation or progress after primary treatment. Patients who stop responding to androgen deprivation therapy develop castration resistant prostate cancer (CRPC). Emerging drugs undergoing clinical evaluation and drugs that have recently received FDA approval for the treatment of CRPC are reviewed. Areas covered: As the natural history and signaling pathways of prostate cancer are better understood, new treatments and targeted therapies will be developed. The FDA recently approved 5 medications that increase survival in patients with CRPC. Additional medications and drug classes are being explored that may eventually lead to new treatment options. Articles were identified using a PubMed database search. Expert opinion: Recent FDA medication approvals and the development of emerging treatments are promising for the future of patients with prostate cancer. The addition of new medications challenges physicians to identify the optimal sequence and/or combination in which newer and older medications should be administered. Physicians treating patients with prostate cancer have a growing responsibility to keep pace with these new medications so that they may counsel and treat patients appropriately.

AB - Introduction: Androgen deprivation therapy is the mainstay treatment for patients with prostate cancer who are not candidates for definitive treatment, are diagnosed with advanced disease on initial presentation or progress after primary treatment. Patients who stop responding to androgen deprivation therapy develop castration resistant prostate cancer (CRPC). Emerging drugs undergoing clinical evaluation and drugs that have recently received FDA approval for the treatment of CRPC are reviewed. Areas covered: As the natural history and signaling pathways of prostate cancer are better understood, new treatments and targeted therapies will be developed. The FDA recently approved 5 medications that increase survival in patients with CRPC. Additional medications and drug classes are being explored that may eventually lead to new treatment options. Articles were identified using a PubMed database search. Expert opinion: Recent FDA medication approvals and the development of emerging treatments are promising for the future of patients with prostate cancer. The addition of new medications challenges physicians to identify the optimal sequence and/or combination in which newer and older medications should be administered. Physicians treating patients with prostate cancer have a growing responsibility to keep pace with these new medications so that they may counsel and treat patients appropriately.

KW - Abiraterone

KW - Androgen deprivation therapy

KW - Androgen receptor

KW - Antiandrogens

KW - Cabazitaxel

KW - Castration resistance

KW - Denosumab

KW - Docetaxel

KW - Emerging drugs

KW - Enzalutamide

KW - Prostate cancer

KW - PSA-TRICOM

KW - Radium-223

KW - Sipuleucel-T

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=84888868894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888868894&partnerID=8YFLogxK

U2 - 10.1517/14728214.2013.864635

DO - 10.1517/14728214.2013.864635

M3 - Article

C2 - 24274615

AN - SCOPUS:84888868894

VL - 18

SP - 533

EP - 550

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 4

ER -